The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments. Key emerging therapies like Amivantamab, BNT113, and Petosemtamab are expected to transform treatment options and expand the market, which was valued at USD 850 million in 2025 across major markets including the US, EU4, UK, and Japan. Advances in immunotherapy, precision medicine, and combination treatments are improving outcomes for patients, while ongoing clinical trials and regulatory designations signal a dynamic and competitive landscape ahead.
One year after the 2025 One Big Beautiful Bill Act (OBBBA) was enacted, a report by the National Association of Manufacturers shows it has significantly benefited the US manufacturing sector. The law, which includes provisions like 100% expensing for...
Amplify CWP Enhanced Dividend Income ETF (DIVO) has gained 6.6% year-to-date but lags the S&P 500 due to high 10-year Treasury yields near 4.62%, which limit dividend stock valuations. The ETF combines blue-chip dividend growers like Johnson & Johnso...
The iShares Core Dividend Growth ETF (DGRO) is facing challenges as the 10-year Treasury yield approaches its 12-month high. This makes DGRO's dividend growth less attractive compared to risk-free Treasury notes. Investors should monitor the 10-year ...
Vanguard High Dividend Yield ETF (VYM) manages $94.6 billion in assets, focusing on large-cap U.S. stocks with high dividend yields. Its top holdings, including Johnson & Johnson and Procter & Gamble, have strong dividend coverage and consistent payo...
The NEOS S&P 500 High Income ETF (SPYI) has returned 8% year-to-date and 19% over the past year, driven mainly by its 12% annualized distribution from selling call options on S&P 500 stocks. However, with market volatility (VIX) decreasing below its ...
